Successful Scale-up of Syphilis Testing Linked to Routine HIV Viral Load Monitoring in British Columbia Authors: Kyle A Thompson, Matthew Clifford-Rashotte, Wendy Zhang, Diana Kao, Jason Trigg, Junine Toy, Silvia Guillemi, Viviane Lima, Rolando Barrios, Julio Montaner, Mark Hull Published: 2026 ABSTRACT AbstractSyphilis rates are increasing, but testing frequency is often inadequate. We examined syphilis screening among people living with human immunodeficiency virus (HIV) in British Columbia between 2015 and 2019. Testing increased significantly during this time and was largely linked to routine HIV viral load monitoring. Frequent testing was associated with men who have sex with men, Vancouver residence, and HIV-focused care.Keywords: MSM, people living with HIV, STI screening, syphilis, viral load monitoring Syphilis, a sexually transmitted infection (STI) caused by the spirochete bacterium Treponema pallidum, has a natural course consisting of multiple infectious stages, followed by a period of latency. Without treatment, up to one-third of individuals may develop late complications that can lead to end-organ disease in the brain and other organ systems [1]. Syphilis rates have been increasing significantly and steadily over the last several decades in British Columbia (BC), nationally within Canada, and globally. Men who have sex with men (MSM) are disproportionately affected by syphilis, although rates are increasing amongst other populations as well [1, 2]. People living with human immunodeficiency virus (HIV; PLHIV) experience a high prevalence of sexual transmitted and blood-borne infections, with syphilis screening recommended every 3–6 months and at minimum annually [3, 4]. In BC, the frequency of syphilis screening among PLHIV is not currently known. Therapeutic guidelines for antiretroviral therapy (ART) of HIV suggest regular assessment and monitoring, with a frequency of viral load testing similar to current syphilis screening recommendations [5]. We sought to determine the frequency of syphilis screening over time among PLHIV engaged in ART and to determine whether screening occurred routinely with viral load testing. METHODS The BC Centre for Excellence in HIV/AIDS (BC-CfE) was established in 1992 as an innovative treatment and research center with the goal of improving the health of PLHIV and those at risk of acquiring HIV. The BC-CfE is responsible for the Drug Treatment Program [6], funded by the provincial government (PharmaCare) to provide antiretroviral medications at no cost to all medically eligible PLHIV and persons at high risk of HIV acquisition living in BC, based on guidelines generated by the BC-CfE's Committee for Drug Evaluation and Therapy [7]. We performed a retrospective analysis of individuals enrolled in the BC Drug Treatment Program between 1 January 2015 and 31 December 2019 to assess the frequency of syphilis screening. In BC, syphilis screening mainly relies on serological testing [3]. A syphilis test was defined as a routine screen if it was performed within 7 days of an HIV viral load measurement. Frequent testing is defined as ≥2 tests per year. Characteristics were compared between those tested and those not tested, using χ2 or Fisher exact tests. The testing trend over years was obtained using the Spearman rank correlation test. We then conducted a multivariate logistic regression to determine variables associated with frequent testing. The model includes MSM status, virologic suppression status, residence, ART provider, testing year, and enrollment duration. MSM status was defined based on the BC-CfE enrollment form completed by the enrolling prescriber. The non-MSM category includes individuals enrolled under heterosexual sexual exposure, injection drug use, or other HIV transmission risk factors. Virologic suppression is defined as viral suppression for ≥50% of the calendar year. The selection of variables was based on 2 criteria: Akaike information criterion and type III P values. These 2 criteria balance the model choice on finding the best explanatory model. The final model has the lowest Akaike information criterion [8]. Statistical analyses were conducted using SAS software (version 9.4; SAS), with the level of significance set at .05. These retrospective analyses of individuals enrolled in the BC Drug Treatment Program were conducted as approved by the University of British Columbia Providence Healthcare Research Ethics Board (no. H05-50123). RESULTS Data were reviewed for a total of 8211 individuals, of whom 7364 (90%) had ≥1 syphilis test over the study period. Most tests conducted (93.4%) were routine screening. The overall proportion of individuals tested per year increased over time (71% in 2015% vs 79% in 2019; P < .001), as did the proportion of those tested who were tested frequently (72% in 2015% vs 83% in 2019; P < .001) (Table 1). Increased testing was observed among MSM (83% in 2015% vs 90% in 2019; P = .005) but not among non-MSM (65% in 2015% vs 72% in 2019; P = .09). Factors associated with frequent syphilis testing include MSM status, residing in Vancouver, and attending an HIV specialty or primary care clinic (Table 2). Virologic suppression status was not retained in the final multivariate model. Table 1.Syphilis Testing by YearYearNo. of ParticipantsIndividuals Tested, No. (%)Total Tests, No.Routine Tests, No. (%)Total≥2 Tests Per Year≥4 Tests Per Year201571805103 (71)3698 (72)917 (18)12 46411 587 (93)201672845449 (75)4228 (78)1818 (33)15 24914 168 (93)201773375612 (76)4504 (80)2059 (37)16 32115 340 (94)201873505708 (78)4634 (81)2104 (37)16 67615 562 (93)201971375635 (79)4682 (83)2141 (38)16 78815 716 (94) P value<.001<.001.005.31 Syphilis Testing by Year Table 2.Multivariate Analysis of Factors Associated With Frequent TestingaVariableUnadjusted OR (95% CI) P ValueAdjusted OR (95% CI) P ValueMSM No (n = 2818)1.00 (Reference)1.00 (Reference) Yes (n = 3166)3.34 (3.08-3.62)<.0011.96 (1.79–2.14)<.001 Unknown (n = 2227)1.22 (1.11–1.33)<.001.85 (.77–.94).001Virologic suppressionb No1.00 Yes1.50 (1.40–1.62)<.001 Unknown0.06 (.03–.13)<.001Residence Elsewhere in BC (n = 5417)1.001.00 West End (n = 1324)2.58 (2.35–2.84)<.0011.57 (1.40–1.75)<.001 Vancouver (n = 1386)1.69 (1.55–1.84)<.0011.26 (1.14–1.38)<.001 Unknown (n = 84)0.70 (.63–.79)<.0010.94 (.82–1.07).36ART provider Other (n = 4106)1.001.00 SPH HIV clinic (n = 1812)5.46 (4.98–5.98)<.0015.18 (4.69–5.72)<.001 HIV specialty clinic (n = 2036)5.13 (4.68–5.64)<.0014.98 (4.38–5.44)<.001 Unknown (n = 257)0.20 (.17–.25)<.0010.27 (.22–.34)<.001Testing year (per 1-y increase)1.13 (1.11–1.14)<.0011.17 (1.15–1.19)<.001Enrollment duration (per 1-mo increase in a year)1.22 (1.21–1.24)<.0011.28 (1.26–1.30)<.001Abbreviations: ART, antiretroviral therapy; BC, British Columbia; CI confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men; OR, odds ratio; SPH, St. Paul′s Hospital. aFrequent testing was defined as ≥2 tests per year. bVirologic suppression was defined as viral suppression for ≥50% of the calendar year. Multivariate Analysis of Factors Associated With Frequent Testinga Abbreviations: ART, antiretroviral therapy; BC, British Columbia; CI confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men; OR, odds ratio; SPH, St. Paul′s Hospital. aFrequent testing was defined as ≥2 tests per year. bVirologic suppression was defined as viral suppression for ≥50% of the calendar year. DISCUSSION Coinfection with syphilis and HIV has been well described in the literature and disproportionately affects MSM. These infections interact synergistically, each increasing the risk of acquisition and transmission of the other in affected individuals [9, 10]. Modeling studies have further demonstrated the strength of this relationship, with 1 model showing that MSM with an HIV diagnosis have >45 times greater syphilis incidence than MSM without HIV [11, 12]. A large cohort study of PLHIV in Ontario, Canada, showed that, by 2009, ≥1 in 5 MSM with HIV had laboratory evidence of current or past syphilis infection [13]. Syphilis testing among PLHIV is generally recommended every 3–6 months, with testing conducted at least once a year, but the frequency of screening is often suboptimal [14–16]. Based on data from the nationally representative Medical Monitoring Project in the United States, nearly one-third of sexually active MSM with HIV were not tested on an annual basis [17]. Our results show that the frequency of syphilis testing among MSM with HIV has been increasing over recent years. The observed increase in syphilis testing over the study period likely reflects the growing syphilis epidemic in BC during this time and increased provider-driven screening in response to rising prevalence. This is consistent with existing recommendations for more frequent STI screening among individuals at elevated risk, including PLHIV [3]. As in our study, consistent and appropriately frequent syphilis testing is achievable by implementing routine syphilis screening into existing HIV care [18–21]. Routine syphilis screening is convenient and well received by both patients and providers [22, 23]. Vancouver residence was associated with increased odds of syphilis testing in our study, which may reflect several urban-specific factors. In BC, Vancouver has a higher burden of syphilis and a concentration of specialized HIV and sexual health services, potentially contributing to increased provider-driven screening and greater patient awareness of testing [24]. Furthermore, higher perceived risk in an urban setting could contribute to increased testing uptake. Factors associated with increased syphilis screening among PLHIV in our study are consistent with those reported in the literature. In the Medical Monitoring Project, patients receiving care from facilities with written STI screening policies were significantly more likely to be screened (94% vs 43%; P < .001) [25]. Participants identifying as male were more likely to be tested in this same study. A retrospective study from the United Kingdom reviewed factors associated with STI screening and syphilis testing among PLHIV [26]. Factors associated with clinicians offering STI screening included patient MSM status (odds ratio [OR], 4.71 [90% confidence interval (CI), 3.04–7.28]), current receipt of ART (2.93 [1.73–4.96]), and multiple sexual partners (4.45 [2.08–9.53]). Factors associated with clinicians offering syphilis testing included male sex (OR, 9.88 [90% CI, 6.59–14.81]) and current receipt of ART (1.57 [1.05–2.35]). In a large cohort study of HIV patients from 2000 to 2009 in Ontario [13], syphilis testing was most common for participants who were MSM (OR, 1.20 [95%, CI, 1.11–1.30]), were aged <30 years (OR for age ≥30 years [age <30 years as referent], 0.89 [95% CI, .81–.97]), had an HIV diagnosis in the current or preceding year (1.29 [1.19–1.41]), had ≥2 routine HIV laboratory tests in that year (1.27 [1.16–1.40]), were tested for syphilis in the previous year (nonreactive result, 1.75 [1.66–1.84]; reactive result, 2.01 [1.89–2.15]), or were ART naive (OR for ART experienced [ART naive as referent], 0.92 [.86–.99). In conclusion, our results show a significant increase in syphilis testing among PLHIV in BC between the 2015 and 2019. The vast majority of syphilis testing is routine screening linked to HIV viral load monitoring. Frequent testing is associated with MSM status, residence in Vancouver, and attending an HIV specialty or primary care clinic. As HIV monitoring becomes less frequent in stable PLHIV, the frequency of syphilis testing may be compromised, and stand-alone testing may become necessary. Notes Data availability . The data underlying this article will be shared on reasonable request to the corresponding author. Contributor Information Kyle A Thompson, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Matthew Clifford-Rashotte, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Wendy Zhang, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Diana Kao, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Jason Trigg, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Junine Toy, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Silvia Guillemi, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Viviane Lima, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Rolando Barrios, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Julio Montaner, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Mark Hull, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. References